Join Drs Steven Feldman and Jonathan Kay as they examine the data on safety, switching, and confidence in psoriasis biosimilars.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-psoriasis-s4-ep4-2026a10006hl. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.  

Resources

Psoriasis https://emedicine.medscape.com/article/1943419-overview

Lyme Disease https://emedicine.medscape.com/article/330178-overview

Synovial Fluid Eosinophilia in Lyme Disease https://pubmed.ncbi.nlm.nih.gov/3056421/

Rheumatoid Arthritis (RA) Treatment & Management https://emedicine.medscape.com/article/331715-treatment

Psoriatic Arthritis Treatment & Management https://emedicine.medscape.com/article/2196539-treatment#d9

A Review of Biosimilars for Rheumatoid Arthritis https://pubmed.ncbi.nlm.nih.gov/35552095/

Drift, Evolution, and Divergence in Biologics and Biosimilars https://pubmed.ncbi.nlm.nih.gov/24567263/

FDA Updates Guidance on Interchangeability https://www.fda.gov/drugs/drug-alerts-and-statements/fda-updates-guidance-interchangeability

Preclinical Rheumatoid Arthritis and Rheumatoid Arthritis Prevention https://pubmed.ncbi.nlm.nih.gov/32205569/

Physicochemical and Biological Similarity Assessment of LBAL, a Biosimilar to Adalimumab Reference Product (Humira®) https://pubmed.ncbi.nlm.nih.gov/34262661/

GP2017, an Adalimumab Biosimilar: Pharmacokinetic Similarity to Its Reference Medicine and Pharmacokinetics Comparison of Different Administration Methods https://pubmed.ncbi.nlm.nih.gov/30698045/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.